Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (NCT06959225)

🧪 Interventions in This Study

• Ruxolitinib Cream (DRUG)
• Vehicle Cream (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (101 Sites)

Showing the first 25 of 101 sites.

• Investigative Site US020 — Phoenix, Arizona
• Investigative Site US033 — Scottsdale, Arizona
• Investigative Site US054 — Tempe, Arizona
• Investigative Site US002 — Fayetteville, Arkansas
• Investigative Site US055 — Brea, California
• Investigative Site US004 — Laguna Niguel, California
• Investigative Site US007 — Los Angeles, California
• Investigative Site US013 — San Diego, California
• Investigative Site US060 — San Diego, California
• Investigative Site US038 — San Diego, California
• Investigative Site US059 — Aurora, Colorado
• Investigative Site US045 — Boynton Beach, Florida
• Investigative Site US028 — Fort Myers, Florida
• Investigative Site US016 — Miami, Florida
• Investigative Site US027 — Sanford, Florida
• Investigative Site US057 — Sweetwater, Florida
• Investigative Site US029 — Tampa, Florida
• Investigative Site US061 — Atlanta, Georgia
• Investigative Site US053 — Atlanta, Georgia
• Investigative Site US019 — Marietta, Georgia
• Investigative Site US026 — Chicago, Illinois
• Investigative Site US049 — Clarksville, Indiana
• Investigative Site US052 — West Lafayette, Indiana
• Investigative Site US001 — Bowling Green, Kentucky
• Investigative Site US022 — Louisville, Kentucky

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
• Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa — Boston, Massachusetts
• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) — Birmingham, Alabama
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Birmingham, Alabama

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.